Biotest Pharmaceuticals names new chief executive

Jordan Siegel is promoted from chief financial officer

Jordan Siegel will become chief executive of Biotest Pharmaceuticals Corporation (BPC), a wholly owned subsidiary of Biotest AG of Dreieich, Germany, on 1 May.

BPC’s interim chief executive, Georg Floss, will return to Germany on 30 April to assume the role of global head of operations at Biotest AG.

Siegel has been BPC’s senior vice president, finance and chief financial officer since its inception in 2007.

BPC researches, develops and manufactures biotherapeutic products for immunology and haematology. The firm is a leader in the collection of source plasma and is currently involved in the development of plasma protein products in the field of Primary Immune Deficiency (PID) and various hyperimmune (IG) products. It owns and manages 12 plasmapherisis centres across the US and a manufacturing facility in Boca Raton, Florida.

You may also like

Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Pharmaceutical

Samsung Bioepis expands European biosimilar portfolio with OBODENCE and XBRYK launches

The products, targeting osteoporosis and bone-related complications in cancer, strengthen access to affordable care and expand the company’s direct sales footprint across endocrinology and oncology
Regulatory

EU approves Sanofi and Regeneron’s Dupixent as first targeted CSU treatment in more than a decade

The European Commission has authorised Dupixent for moderate-to-severe chronic spontaneous urticaria in patients aged 12+, offering the first new targeted option in more than ten years
Regulatory

FDA grants Medivir’s MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta treatment

The FDA has awarded Orphan Drug Designation to Medivir’s selective cathepsin K inhibitor MIV-711 for Osteogenesis Imperfecta, a rare genetic bone disorder, after preclinical and clinical data suggests the therapy may strengthen bone
Sustainability

Solvent recyclers improve HPLC system sustainability

A leading pharmaceutical company has purchased 17 SPR-200 solvent recycler units from Biotech Fluidics improving sustainable use of solvents by HPLC systems in their analytical laboratories
Pharmaceutical

Polpharma Biologics announces US launch of Tyruko, the first FDA-approved natalizumab biosimilar for MS

Tyruko is now available to US patients with multiple sclerosis and Crohn’s disease, expanding access to a more affordable biologic option
Research & Development

Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development

Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies
Subscribe now